Stemnion, Inc. is a regenerative medicine company focused on the research, development, and clinical use of therapeutic products obtained from amnion-derived, non-embryonic stem cells also known as placental stem cells.  The technology provides a new approach to wound healing and tissue repair.  There is no interruption in the development of the baby to procure this tissue, and therefore there are no ethical, religious, moral or political issues associated with its use. Stemnion’s products are being developed to promote better healing in a wide range of conditions and injuries.  Stemnion collaborates with major research centers to advance these therapeutic applications and has initiated clinical trials.  The first product, Amnion-derived Cellular Cytokine Solution (ACCS,) has been used in a Phase I safety clinical trial in the United States for the treatment of burns.